Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Position Boosted by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 72.2% in the 4th quarter, HoldingsChannel reports. The fund owned 21,330 shares of the medical research company’s stock after acquiring an additional 8,946 shares during the period. Tower Research Capital LLC TRC’s holdings in Thermo Fisher Scientific were worth $11,097,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in TMO. Tradition Wealth Management LLC grew its holdings in Thermo Fisher Scientific by 6.5% during the fourth quarter. Tradition Wealth Management LLC now owns 1,201 shares of the medical research company’s stock worth $625,000 after acquiring an additional 73 shares during the period. Transce3nd LLC acquired a new position in Thermo Fisher Scientific during the fourth quarter valued at $64,000. Kelly Lawrence W & Associates Inc. CA lifted its stake in Thermo Fisher Scientific by 51.5% in the 4th quarter. Kelly Lawrence W & Associates Inc. CA now owns 500 shares of the medical research company’s stock worth $260,000 after acquiring an additional 170 shares in the last quarter. Mirova grew its stake in Thermo Fisher Scientific by 1.5% during the 4th quarter. Mirova now owns 161,861 shares of the medical research company’s stock valued at $84,205,000 after acquiring an additional 2,390 shares in the last quarter. Finally, MetLife Investment Management LLC increased its holdings in shares of Thermo Fisher Scientific by 1.9% in the 4th quarter. MetLife Investment Management LLC now owns 101,234 shares of the medical research company’s stock valued at $52,665,000 after purchasing an additional 1,901 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the sale, the chief executive officer now owns 115,174 shares in the company, valued at approximately $59,506,950.58. The trade was a 7.99 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the completion of the transaction, the executive vice president now owns 16,363 shares of the company’s stock, valued at $9,582,009.17. The trade was a 1.80 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 23,900 shares of company stock worth $13,106,062. 0.34% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Down 2.4 %

Shares of TMO opened at $426.11 on Friday. The business’s fifty day moving average price is $497.67 and its two-hundred day moving average price is $533.09. The firm has a market capitalization of $160.85 billion, a price-to-earnings ratio of 25.78, a PEG ratio of 2.99 and a beta of 0.86. Thermo Fisher Scientific Inc. has a 52 week low of $409.85 and a 52 week high of $627.88. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. On average, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th were issued a $0.43 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a dividend yield of 0.40%. The ex-dividend date of this dividend was Friday, March 14th. Thermo Fisher Scientific’s dividend payout ratio is 10.41%.

Analysts Set New Price Targets

A number of research analysts recently commented on TMO shares. Barclays lowered their price objective on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 10th. Morgan Stanley upped their price target on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an “overweight” rating in a research note on Friday, January 31st. UBS Group boosted their target price on Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a “buy” rating in a research note on Friday, January 31st. StockNews.com upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th. Finally, Citigroup decreased their target price on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Four equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $642.67.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.